Anti-D Alloimmunization after RhD-Positive Platelet Transfusion in RhD-Negative Women under 55 Years Diagnosed with Acute Leukemia: Results of a Retrospective Study
Autor: | José María Fernández, Pau Montesinos, Miguel A. Sanz, Ana Villalba, Carolina Fuentes, Carmen Freiria, Inés Gómez, Pilar Solves, Nelly Carpio, Marta Santiago, Rebeca Rodríguez-Veiga, Guillermo Sanz |
---|---|
Rok vydání: | 2018 |
Předmět: |
medicine.medical_specialty
Acute leukemia Acute myeloblastic leukemia business.industry Secondary Acute Myeloblastic Leukemia RhD positive Retrospective cohort study Hematology 030204 cardiovascular system & hematology medicine.disease Anti-D alloimmunization 03 medical and health sciences 0302 clinical medicine Platelet transfusion Internal medicine RhD negative Immunology and Allergy Medicine Platelet business 030215 immunology Research Article |
Zdroj: | TRANSFUSION MEDICINE AND HEMOTHERAPY r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname |
ISSN: | 1660-3796 |
Popis: | Background: Anti-D alloimmunization can occur when platelets from RhD-positive donors are transfused to RhD-negative patients, due to red blood cell residues in the platelet concentrates. Methods: Our objective was to analyze the anti-D alloimmunization rate in a selected group of women under 55 years of age diagnosed with acute leukemia over an 18-year period. We focused the analysis on RhD-negative patients who received RhD-positive platelet transfusions. Results: From January 1998 to October 2016, 382 women under 55 years were diagnosed with acute leukemia. A total of 56 patients were RhD-negative, and 48 (85.7%) received RhD-positive platelets. The median number of platelet concentrates transfused per patient was 23, and 48% of all platelet transfusions were RhD-positive. The 48 RhD-negative patients received a total of 949 RhD-positive platelet concentrates. Two patients developed anti-D: a 36-year-old woman with M3 acute myeloblastic leukemia and a 52-year-old patient with a secondary acute myeloblastic leukemia. Conclusion: We conclude that there is a need for agreement in the transfusion guidelines on the recommendation of anti-D alloimmunization prophylaxis. We suggest a possible benefit in favor of anti-D prophylaxis in childbearing women with acute leukemia. |
Databáze: | OpenAIRE |
Externí odkaz: |